Hypertrophic cardiomyopathy
Diagnosis by wall thickness, LVOT obstruction and its drugs, myosin inhibitors and the PBS, sudden death risk and ICDs, phenocopies, AF and family screening.
Tier 1Condition
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- The commonest inherited heart disease: unexplained LV hypertrophy in about 1 in 500 adults. Mostly autosomal dominant sarcomere gene variants.
- Diagnosis: wall thickness ≥15 mm (≥13 mm in a first-degree relative) not explained by loading conditions.
- About two-thirds have LV outflow tract obstruction at rest or on provocation, which drives symptoms and is the target of most treatment.
Loading the rest of the note…
Finished reading?
Sources
- Assessing Fitness to Drive (AP-G56), cardiovascular conditions: medical standards for licensing (hypertrophic cardiomyopathy, ICD)AU/NZAustroads and National Transport Commission, 2022
- Arbelo E, Protonotarios A, Gimeno JR et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023;44:3503-3626. doi:10.1093/eurheartj/ehad194European Society of Cardiology, 2023
- Ommen SR, Ho CY, Asif IM et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the management of hypertrophic cardiomyopathy. Circulation 2024;149:e1239-e1311American Heart Association and American College of Cardiology, 2024
- Government adds two new heart disease treatments on the PBS (mavacamten listing, 1 May 2024)AU/NZAustralian Government Minister for Health and Aged Care, 2024
- Mavacamten, Public Summary Document, November 2023 PBAC meetingAU/NZPharmaceutical Benefits Advisory Committee, 2023
- PBS Schedule: mavacamten (Camzyos) for symptomatic obstructive HCM, initial, first continuing and maintenance restrictions (checked November 2026)AU/NZAustralian Government Department of Health, Disability and Ageing, 2026
- Symptomatic obstructive hypertrophic cardiomyopathy: mavacamten initial authority application (PB360)AU/NZServices Australia (PBS), PB360.2506 (June 2025)
- Olivotto I, Oreziak A, Barriales-Villa R et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM). Lancet 2020;396:759-769The Lancet, 2020
- Garcia-Pavia P, Maron MS, Masri A et al. Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy (MAPLE-HCM). N Engl J Med 2025;393:949-960New England Journal of Medicine, 2025
- Desai MY, Owens AT, Abraham T et al. Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy (ODYSSEY-HCM). N Engl J Med 2025;393:961-972New England Journal of Medicine, 2025
- Legislation passed to ban the use of adverse genetic testing results in life insuranceAU/NZAustralian Treasury (ministerial media release), 2026
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback